Abstract
Chemotherapeutic Agents for Brain Metastases in Non-Small Cell Lung Cancer: A Case Report with Eribulin Mesylate and Review of the Literature
Highlights
Lung cancer is the leading cause of cancer-related deaths, accounting for nearly 27% in the United States and 20% worldwide [1,2]
The current standard of care for the treatment of brain metastases is still limited to surgery and radiation
With partial response and continued stabilization of brain metastases (BM), demonstrates how effective systemic treatment can be for intracranial metastases even after they have become refractory to whole brain radiation therapy (WBRT)
Summary
Lung cancer is the leading cause of cancer-related deaths, accounting for nearly 27% in the United States and 20% worldwide [1,2]. CT imaging on December 30th showed progression of disease, with bony metastases in the left 10th rib and left iliac wing Given her recurrent brain metastases, which at this point represented the most serious problem facing this patient, we selected drugs that had a reasonable probability to penetrate into the CNS and to be effective with her lung cancer. A MRI brain scan in March 2014 (three months into targeted treatment) showed decreased metastatic burden, including smaller parietal (0.8 cm) (Figure 1B), basal ganglia (1.1 cm), and cerebellar (0.6 cm) lesions. PET scan showed progression with multiple new FDG-avid bony metastases She developed a pathological fracture of her left femoral neck and underwent hemiarthroplasty in June 2014, which was complicated by a septic left hip joint in October 2014 and resulted in therapy being stopped. She never developed any new neurologic symptoms that would suggest clinical progression of BM
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
